---
title: "Chromeno[8,7-d]oxazole Lead AT-11: A CDK16 Inhibitor with Improved Solubility and Antitumor Activi"
id: "pubmed-42822357"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42822357"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42822357/"
doi: "10.1016/j.bioorg.2026.110559"
published_at: "2026-11-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Chromeno[8,7-d]oxazole Lead AT-11: A CDK16 Inhibitor with Improved Solubility and Antitumor Activi
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42822357
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42822357/)
- **DOI:** [10.1016/j.bioorg.2026.110559](https://doi.org/10.1016%2Fj.bioorg.2026.110559)
- **Published At:** 2026-11-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Investigators designed a series of **chromeno[8,7-d]oxazole** derivatives from a CDK9-preferring hit (HS-36) by modifying the C-8 side chain and N-1 substituent. - The team identified AT-11 as the most potent analog against **CDK16/Cyclin Y (CDK16/CycY)**, reporting an IC50 of 125.2 nM in their kinase assay. - Single-concentration kinase comparisons indicated a relative shift away from CDK9 toward CDK16 inhibition versus HS-36. - AT-11 solubility measured 617 μg/mL in PBS at pH 7.4, a marked formulation-relevant property noted by the authors. - In H460 non–small cell lung cancer cells, AT-11 reduced proliferation and colony formation, induced S-phase accumulation, increased apoptosis, and decreased migration. - Across an expanded panel, AT-11 showed differential antiproliferative activity with low-micromolar GI50 values reported for H460, A549, and MV-4-11 cell lines. - Western blot in H460 cells after AT-11 exposure revealed decreased p53 Ser315 phosphorylation alongside increased total p53 levels. - In vivo, intravenous AT-11 at 20 mg/kg produced 48.2% tumor growth inhibition in an H460 xenograft model without notable body-weight loss or apparent histopathological abnormalities under the tested conditions. - The study positions AT-11 as an early-stage lead for **CDK16**-directed drug development and extends structure-activity relationships for this scaffold. - The abstract did not report detailed assay protocols, full kinase selectivity panels, comprehensive pharmacokinetics, or chronic toxicity data; those methodological specifics were not provided in the source.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42822357/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42822357%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42822357/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42822357/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42822357/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42822357/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42822357/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42822357%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42822357%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42822357/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42822357/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42822357/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42822357/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0045-2068\(26\)01095-3 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42822357/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42822357/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42822357/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42822357/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42822357/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42822357/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42822357/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42822357/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42822357/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42822357/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Bioorg Chem Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bioorg+Chem%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Bioorg+Chem%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) . 2026 Nov 5:183:110559. doi: 10.1016/j.bioorg.2026.110559. Epub 2026 Sep 22. # Rational design of chromeno[8,7-d]oxazoles as CDK16-directed inhibitors with improved solubility and antitumor activity [Xupeng Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+X&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Cuibin Kong](https://pubmed.ncbi.nlm.nih.gov/?term=Kong+C&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Yaoguang Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+Y&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Xiaoyu Shi](https://pubmed.ncbi.nlm.nih.gov/?term=Shi+X&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Zheng Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Z&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Jingming Jia](https://pubmed.ncbi.nlm.nih.gov/?term=Jia+J&cauthor_id=42822357)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-2 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: jiajingming@syphu.edu.cn."), [Anhua Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+A&cauthor_id=42822357)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#full-view-affiliation-3 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: sywanganhua@163.com.") Affiliations Expand ### Affiliations * 1 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. * 2 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: jiajingming@syphu.edu.cn. * 3 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: sywanganhua@163.com. * PMID: **42822357** * DOI: [ 10.1016/j.bioorg.2026.110559 ](https://doi.org/10.1016/j.bioorg.2026.110559) Item in Clipboard # Rational design of chromeno[8,7-d]oxazoles as CDK16-directed inhibitors with improved solubility and antitumor activity Xupeng Yang et al. Bioorg Chem. 2026. Show details Display options Display options Format Abstract PubMed PMID Bioorg Chem Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bioorg+Chem%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Bioorg+Chem%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) . 2026 Nov 5:183:110559. doi: 10.1016/j.bioorg.2026.110559. Epub 2026 Sep 22. ### Authors [Xupeng Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+X&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Cuibin Kong](https://pubmed.ncbi.nlm.nih.gov/?term=Kong+C&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Yaoguang Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+Y&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Xiaoyu Shi](https://pubmed.ncbi.nlm.nih.gov/?term=Shi+X&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Zheng Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Z&cauthor_id=42822357)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-1 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China."), [Jingming Jia](https://pubmed.ncbi.nlm.nih.gov/?term=Jia+J&cauthor_id=42822357)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-2 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: jiajingming@syphu.edu.cn."), [Anhua Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+A&cauthor_id=42822357)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42822357/#short-view-affiliation-3 "School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: sywanganhua@163.com.") ### Affiliations * 1 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. * 2 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: jiajingming@syphu.edu.cn. * 3 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.. Electronic address: sywanganhua@163.com. * PMID: **42822357** * DOI: [ 10.1016/j.bioorg.2026.110559 ](https://doi.org/10.1016/j.bioorg.2026.110559) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Acquired resistance to established molecularly targeted therapies remains a major challenge in non-small cell lung cancer (NSCLC). In this study, a series of chromeno[8,7-d]oxazole derivatives was designed from the CDK9-preferring hit HS-36 through structure-guided modification of the C-8 side chain and N-1 substituent. Among these derivatives, AT-11 showed the strongest inhibition of CDK16/Cyclin Y (CDK16/CycY), with an IC50 value of 125.2 nM. Single-concentration measurements performed under the same kinase assay conditions were consistent with a relative shift in the CDK16/CDK9 inhibitory profile compared with HS-36. AT-11 showed a solubility of 617 μg/mL in PBS (pH 7.4). In H460 cells, AT-11 inhibited proliferation and colony formation, was associated with S-phase accumulation and increased apoptosis, and reduced cell migration. Across an expanded panel of tumor and comparator cell lines, AT-11 displayed differential antiproliferative activity, with low-micromolar GI50 values in H460, A549, and MV-4-11 cells. Western blot analysis in H460 cells showed reduced relative p53 Ser315 phosphorylation and increased total p53 levels following AT-11 treatment. Intravenous administration of AT-11 at 20 mg/kg produced 48.2% tumor growth inhibition in an H460 xenograft model without marked body-weight loss or apparent histopathological abnormalities under the tested conditions. These findings identify AT-11 as an early-stage chromeno[8,7-d]oxazole lead and extend the structure-activity basis for CDK16-directed inhibitor development. **Keywords:** Antitumor activity; CDK16 inhibitors; Chromeno[8,7-d]oxazoles; NSCLC; Structure-based drug design. Copyright © 2026. Published by Elsevier Inc. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model. ](https://pubmed.ncbi.nlm.nih.gov/35883026/) Li J, Yuan J, Li Y, Wang J, Gong D, Xie Q, Ma R, Wang J, Ren M, Lu D, Xu Z.Li J, et al.Cell Mol Biol Lett. 2022 Jul 26;27(1):61. doi: 10.1186/s11658-022-00362-4.Cell Mol Biol Lett. 2022.PMID: 35883026Free PMC article. * [ Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70. ](https://pubmed.ncbi.nlm.nih.gov/28004121/) Zhou Y, Ma J, Zhang J, He L, Gong J, Long C.Zhou Y, et al.Oncol Rep. 2017 Jan;37(1):313-322. doi: 10.3892/or.2016.5286. Epub 2016 Nov 29.Oncol Rep. 2017.PMID: 28004121 * [ Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies. ](https://pubmed.ncbi.nlm.nih.gov/22261315/) Xue X, Sun DF, Sun CC, Liu HP, Yue B, Zhao CR, Lou HX, Qu XJ.Xue X, et al.Lung Cancer. 2012 Jun;76(3):300-8. doi: 10.1016/j.lungcan.2011.12.013. Epub 2012 Jan 17.Lung Cancer. 2012.PMID: 22261315 * [ Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells. ](https://pubmed.ncbi.nlm.nih.gov/34311158/) Liu J, Ye W, Xu JP, Wang HT, Li XF, Wang WY, Zhou ZZ.Liu J, et al.Eur J Med Chem. 2021 Nov 15;224:113700. doi: 10.1016/j.ejmech.2021.113700. Epub 2021 Jul 15.Eur J Med Chem. 2021.PMID: 34311158 * [ Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. ](https://pubmed.ncbi.nlm.nih.gov/36321557/) Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.Crider K, et al.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.Cochrane Database Syst Rev. 2022.Update in: [Cochrane Database Syst Rev. 2026 Feb 18;2:CD014217. doi: 10.1002/14651858.CD014217.pub2.](https://pubmed.ncbi.nlm.nih.gov/41705996/)PMID: 36321557Free PMC article.Updated. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42822357) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * Antineoplastic Agents* / chemical synthesis Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fchemical+synthesis%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * Antineoplastic Agents* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * Antineoplastic Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * Apoptosis / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Apoptosis%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Apoptosis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42822357/) * Cell Proliferation / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Proliferation%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Proliferation) * [ Add to Search ](https://p
## Related Clinical Research

- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [XDH and ITPA linked to prognosis and cisplatin response in NSCLC: integrated bioinformatics and la](https://medichelpline.com/clinical-feed/pubmed-42972208.md) (DOI: 10.1007/s10142-026-02100-x)
- [CLDN18.2 targeting increases chemotherapy sensitivity in pancreatic and lung cancer models](https://medichelpline.com/clinical-feed/pubmed-42772182.md) (DOI: 10.1016/j.bbrc.2026.154610)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.